|
HHS Panel on Antiretroviral Guidelines for Adults and Adolescents
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA
|
NICHD, NIAID, OD/DPCPSI/OAR
|
The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) is a working group of the Office of AIDS Research Advisory Council (OARAC). The primary goal of the Panel is to provide HIV care practitioners with recommendations based on current knowledge of antiretroviral drugs (ARVs) used to treat adults and adolescents with HIV in the United States. The Panel reviews new evidence and updates recommendations when needed. These guidelines include recommendations on baseline laboratory evaluations, treatment goals, benefits of ART and considerations when initiating therapy, choice of the initial regimen for ART-naive patients, ARV drugs or combinations to avoid, management of treatment failure, management of adverse effects and drug interactions, and special ART-related considerations in specific patient populations.
|
|
HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA
|
NICHD, NIAID, OD/DPCPSI/OAR
|
This committee has the purpose of updating the U.S. Pediatric HIV treatment guidelines and serves as executive secretary. The Department's Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children (the Panel), a working group of the Office of AIDS Research Advisory Council, reviews new data on an ongoing basis, and provides regular updates to the guidelines. The guidelines are available on the AIDSinfo website. These updated guidelines address the use of combination antiretroviral therapy for HIV-infected infants, children, and adolescents. Guidance on management of adverse events associated with use of antiretroviral drugs in children and a detailed review of information about safety, efficacy, and pharmacokinetics of antiretroviral agents in children is also included.
|
|
HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA
|
NICHD, NIAID, OD/DPCPSI/OAR
|
Also called 'Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States'. These Guidelines update the October 2016 Perinatal Guidelines. The Department of Health and Human Services Panel on Treatment of Pregnant Women Living with HIV and Prevention of Perinatal Transmission (the Panel), a working group of the Office of AIDS Research Advisory Council, develops these guidelines. The guidelines provide health care providers with information for discussion with pregnant women living with HIV infection to enable collaborative, informed decision-making regarding the use of ARV drugs during pregnancy, use of scheduled cesarean delivery to reduce perinatal transmission of HIV, and decision-making around the use of ARV drugs for prophylaxis of infants exposed to HIV. The recommendations in these Guidelines are accompanied by a discussion of various circumstances that commonly occur in clinical practice and the factors that influence treatment considerations. The Panel recognizes that strategies to prevent perinatal transmission and concepts related to management of HIV in pregnant women are rapidly evolving and will consider new evidence and adjust recommendations accordingly. The updated guidelines are available from the AIDSinfo website http://aidsinfo.nih.gov.
|
|
HHS Potential Pandemic Pathogens Care and Oversight Review Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
Evaluates proposed research being considered for Department of Health and Human Services (HHS) funding that is anticipated to create, transfer, or use enhanced potential pandemic pathogen (enhanced PPP)--as defined in the Department of Health and Human Services Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens (HHS P3CO Framework)--to inform agency funding decisions.
|
|
HHS SARS-CoV-2 Assay Development Task orders
|
Resource Development
|
BARDA
|
NIAID
|
Assays are being developed, qualified and validated to be shared across government studies
|
|
HHS SARS-CoV-2 Immune Assay Testing of Ph3 clinical samples- Task Order
|
Resource Development
|
BARDA
|
NIAID
|
Coordination of testing of Phase 3 clinical samples from Operation War Speed (OWS) peformers in OWS Assays (Microneutralization assay)
|
|
HHS Tick-Borne Diseases Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, CMS, FDA, OS
|
NIAID
|
The Tick-Borne Disease Working Group was established by Congress in 2016 as part of the 21st Century Cures Act to provide subject matter expertise and to review federal efforts related to all tick-borne diseases, to help ensure interagency coordination and minimize overlap, and to examine research priorities. The focus of this effort is the development of a report to the Secretary of Health and Human Services and Congress on the findings and any recommendations of the Working Group for the federal response to tick-borne disease prevention, treatment, and research, as well as how to address gaps in these areas.
|
|
HHS Viral Hepatitis Interagency Working Group
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA
|
NIDDK, NIDA, NIAID, OD/DPCPSI/OAR
|
The Department of Health and Human Services (HHS) Viral Hepatitis Interagency Working Group was created by the Office of the Assistant Secretary for Health to address a report sponsored by the Institute of Medicine entitled Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. The group meets to discuss collaborations and activities directed at achieving the goals for viral hepatitis research and control highlighted in the IOM report. (Although the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute on Drug Abuse (NIDA) represent the National Institutes of Health (NIH) as Working Group members, other NIH Institutes/Centers/Offices also provide input to the VHIG through their participation in the Trans-NIH Committee on Viral Hepatitis.) The working group helped develop the 2021-2025 Viral Hepatitis National Strategic Plan.
|
|
HHS Zika Vaccine Testing Task Orders Coordination
|
Resource Development
|
BARDA
|
NIAID
|
Zika vaccine testing contract efforts are being coordinated through this Department of Health and Human Services (HHS) partner meeting.
|
|
HHS-NASA Scientific Potential/Actual Collaborative Efforts (SPACE) group
|
Committee, Work group, Advisory group, or Task Force
|
ACL, CDC, FDA
|
NCATS, FIC, NCI, NEI, NHLBI, NIA, NIAID, NIAMS, NIBIB, NICHD, NIDCR, NIDDK, NIEHS, NIMH, NIMHD, NINDS, OD/IMOD
|
Scientific interest group joint with the National Aeronautics and Space Administration (NASA) and other Department of Health and Human Services (HHS) OpDivs convened to explore areas of potential joint collaborative interest.
|